<DOC>
	<DOCNO>NCT03043521</DOCNO>
	<brief_summary>The purpose study compare evaluate impact pharmacodynamic characteristic CJ-12420 dexlansoprazole even dose healthy male volunteer</brief_summary>
	<brief_title>Pharmacodynamic Properties CJ-12420 Evening Dosing</brief_title>
	<detailed_description>Evaluation Criteria : 1 . Pharmacokinetic Endpoints Cmax , tmax , AUClast CJ-12420 2 . Pharmacodynamics Endpoints Time pH &gt; 4 Time pH &gt; 6 Integrated acidity Percent inhibition integrate acidity Percent inhibition time gastric pH ≤ 4 Median pH 3 . Safety Assessments Physical examination , ECGs , vital sign ( blood pressure , heart rate , body temperature ) , laboratory test ( CBC , Chemistry , UA ) , adverse event ( AEs )</detailed_description>
	<mesh_term>Dexlansoprazole</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<criteria>1 . Healthy male volunteer age ≥20 ≤45 year 2 . Body mass Index ( BMI ) 19 28kg/m2 ; total body weight ≥ 50kg 3 . Medically healthy without clinically significant vital sign ( blood pressure sit position , heart rate ) 90 mmHg ≤ Systolic blood pressure ( SBP ) ≤ 140 mmHg 50 mmHg ≤ Diastolic blood pressure ( DBP ) ≤ 95 mmHg 45 ( beats/min ) ≤ Heart rate ≤ 95 ( beats/min ) 4 . Understand restriction study voluntarily consent participate study 5 . Consent use effective contraceptive method ( use abstinence , spermicide , condom ) donate sperm study 30 day completion study 6 . Nonsmoker exsmoker stop smoke least one year 7 . Negative H. pylorus result urea breath test ( UBT ) 1 . History clinically significant disease digestive , kidney , liver , nervous , hematooncologic , endocrine , respiratory , immune , psychiatric , musculoskeletal , cardiovascular system disease may harm safety subject may affect validity study result , judgment investigator 2 . History allergy hypersensitivity drug include serious adverse event treatment PPI ( omeprazole , rabeprazole , lansoprazole ) PCAB 3 . History surgery may affect absorption , distribution , metabolism , elimination study drug medical condition , discretion principal investigator subinvestigator 4 . History use another investigational product within 90 day prior screen visit 5 . Donation unit whole blood within 60 day blood component transfusion within 30 day prior screen visit 6 . Having special diet change dietary habit within 30 day prior screen visit 7 . Use prescription drug within 14 day overthecount ( OTC ) drug include herbal medicine within 7 day prior screen visit 8 . Alcohol &gt; 21 units/week 9 . Caffeinated drink intake &gt; 5units/day 10 . Positive urinary drug screen test urine nicotine test 11 . Positive human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C , syphilis test 12 . Clinically significant abnormal result liver function ( serum ALT , AST total bilirubin level ≥ 1.5 time upper limit normal ( ULN ) ) 13 . Inability tolerate pH catheter insertion 14 . History symptomatic GERD , erosive esophagitis ( EE ) , duodenal ulcer , gastric ulcer , Barrett 's esophagus , ZollingerEllison Syndrome 15 . Any condition would make subject unsuitable study opinion investigator</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>